Federation des caisses Desjardins du Quebec’s Recursion Pharmaceuticals RXRX Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$64.9K	Buy	17,691 +2,290	+15%	+$7.62K	﹤0.01%	1858
2026 Q1	$47.3K	Buy	15,401 +3,310	+27%	+$12.8K	﹤0.01%	1878
2025 Q4	$49.5K	Sell	12,091 -1,035	-8%	-$5.13K	﹤0.01%	1819
2025 Q3	$64.1K	Sell	13,126 -19,965	-60%	-$105K	﹤0.01%	1749
2025 Q2	$167K	Sell	33,091 -12,000	-27%	-$59K	﹤0.01%	1264
2025 Q1	$239K	Buy	45,091 +2,000	+5%	+$14.6K	﹤0.01%	1144
2024 Q4	$291K	Buy	43,091 +591	+1%	+$3.97K	﹤0.01%	1074
2024 Q3	$280K	Sell	42,500 -3,500	-8%	-$25.1K	﹤0.01%	1076
2024 Q2	$345K	Hold	46,000	–	–	﹤0.01%	1018
2024 Q1	$459K	Buy	46,000 +1,900	+4%	+$21.2K	﹤0.01%	902
2023 Q4	$435K	Hold	44,100	–	–	﹤0.01%	805
2023 Q3	$337K	Buy	+44,100	New	+$440K	﹤0.01%	830

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's RXRX Position: Q2 2026 in Review

Federation des caisses Desjardins du Quebec increased its Recursion Pharmaceuticals (RXRX) stake by 15% in Q2 2026, buying an estimated $7.62K and bringing the position to 17,691 shares worth $64.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1858.

Federation des caisses Desjardins du Quebec first reported a position in RXRX in Q3 2023 and has held it in 12 quarters since. The position peaked at $459K in Q1 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Federation des caisses Desjardins du Quebec held 17,691 shares of Recursion Pharmaceuticals worth $64.9K as of Q2 2026.
Federation des caisses Desjardins du Quebec bought 2,290 Recursion Pharmaceuticals shares in Q2 2026, an estimated $7.62K.
Recursion Pharmaceuticals made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q2 2026, its #1858 holding.
Federation des caisses Desjardins du Quebec first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Federation des caisses Desjardins du Quebec's Recursion Pharmaceuticals position peaked at $459K in Q1 2024.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2026, filed 14 Aug 2026.